Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Auditor change
Inv. presentation
Acq. announced
Director departure
Appointed director

Emmaus Life Sciences, Inc. (MYND) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Emmaus Life Sciences Reports Management Changes"
08/14/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Emmaus Life Sciences Reports Q2 2023 Financial Results"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/02/2023 4 LEE WILLIS C (COO) has filed a Form 4 on Emmaus Life Sciences, Inc.
Txns: Bought 750 shares @ $0.28, valued at $210
Bought 28,700 shares @ $0.29, valued at $8.3k
05/15/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update Torrance CA, May 15, 2023 - Emmaus Life Sciences, Inc. , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2023. Recent Highlights “We enjoyed a fifth straight increase in quarterly net revenues and increased net revenues of 109% year-over-year on the strength of increased sales in the U.S. and the Middle East North Africa region. As a result, we were able to substantially reduce loss from operations and realized income from operations excluding share-based compensation. We hope to build on this momentum and achieve income from operations in the co..."
03/31/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update"
03/31/2023 10-K Annual Report for the period ended December 31, 2022
01/31/2023 D Form D - Notice of Exempt Offering of Securities:
01/20/2023 4 ZEN Wei Peu (Director) has filed a Form 4 on Emmaus Life Sciences, Inc.
Txns: Bought 2,000,000 options to buy @ $0.5, valued at $1M
01/20/2023 D Form D - Notice of Exempt Offering of Securities:
01/19/2023 4/A LEE WILLIS C (COO) has filed a Form 4 on Emmaus Life Sciences, Inc.
Txns: Granted 500,000 options @ $4.5, valued at $2.3M
01/19/2023 8-K Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce...
01/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/17/2023 4 Niihara Yutaka (Chairman and CEO) has filed a Form 4 on Emmaus Life Sciences, Inc.
Txns: Granted 7,500,000 warrants @ $4.5, valued at $33.8M
12/09/2022 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
12/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/14/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/09/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/03/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/31/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/31/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
10/24/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/21/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
10/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/17/2022 4 Niihara Yutaka (Chairman and CEO) has filed a Form 4 on Emmaus Life Sciences, Inc.
Txns: Bought 62,500 shares @ $0.18, valued at $11.3k
Bought 35,000 shares @ $0.17, valued at $6k
10/13/2022 4 Niihara Yutaka (Chairman and CEO) has filed a Form 4 on Emmaus Life Sciences, Inc.
Txns: Bought 5,000 shares @ $0.09, valued at $450
Bought 160,000 shares @ $0.08, valued at $12.8k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy